Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Stopped early · Phase 1/Phase 2

Conditions studied: Type 2 Diabetes

In brief

The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.

Key facts

Study ID

NCT00609154

Run by

Albert Einstein College of Medicine

People needed

20

Starts

2010-08-12

Expected to finish

2014-05-13

Last updated by the study team

2024-02-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Type 2 Diabetes
• Non diabetic

You may not qualify if…

• Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin
• Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)
• Anemia

Where it is running

• Albert Einstein College of Medicinie — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.